AMGEN INC Earnings Summary — Q1 2026
Amgen Posts Solid Q1 2026 Performance with Continued Revenue Growth and Margin Stabilization
Key Takeaways
- Revenue reached $8.6B for Q1 2026, a 5.75% increase year-over-year, supported by Horizon integration.
- Net income improved to $1.8B, bouncing back from a volatile 2024-2025 period involving heavy M&A amortization.
- Operating income of $2.67B demonstrates improved operational discipline following the Horizon acquisition.
- R&D investment remains high at $1.72B (20% of revenue) as the company focuses on the MariTide obesity pipeline.
- Interest expenses remain a significant headwind at $657M per quarter due to high leverage from recent acquisitions.
- Gross margins remained steady near 68%, slightly compressed compared to historical peaks above 75%.
- Diluted EPS improved to $3.37 for the quarter, reflecting a stabilization in share count and earnings power.
Management Guidance
Management is focused on navigating the Inflation Reduction Act's impact on drug pricing while prioritizing the development of high-growth assets in oncology and rare diseases.
Sentiment Shift
Improving
The company shows clear signs of stabilizing its margin profile and net income growth after a period of intense acquisition-related volatility.
Outlook
Amgen is expected to maintain its trajectory of 10-year revenue CAGR around 3.8%, bolstered by the ramp-up of TEPEZZA and Repatha and a robust clinical pipeline in the obesity market.
From the Annual Report (Key Quotes)
“The transition from a legacy biologics provider to a diversified innovator in oncology and rare diseases is yielding results.”
“Strategic $27.8B acquisition of Horizon Therapeutics continues to support the underlying operating cash flow.”
“Management remains proactive regarding the Inflation Reduction Act and global supply chain complexities.”
Official Quarterly Documents
This summary is AI-generated from AMGEN INC's latest quarterly filing and earnings call. For informational purposes only — not investment advice.